Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Orbital Decompression for Thyroid Eye Disease: Outcomes by Preoperative Severity and Technique
Peraza, Lazaro R. , Fearington, Forrest W. , Hernandez-Herrerra, Gabriel A., Tooley, Andrea A. , Stokken, Janalee K. , Awadallah, Andrew S. , Carlson, Matthew L , Wagner, Lilly H. , Bradley, Elizabeth A. , Stan, Marius N.

American Journal of Rhinology & Allergy | April 10, 2025 | Volume: 39 | Issue: 4 | Pages: 284-292

10.1177/19458924251330947 | PMID 40207636 Get It

Background Orbital decompression is an essential tool for reducing proptosis in thyroid eye disease (TED), yet the impact of surgical approach and preoperative factors on outcomes remains uncertain. Objective To compare proptosis reduction following different orbital decompression techniques, identify additional risk factors that may play a role in surgical orbital decompression outcomes, and develop clinical decision-making recommendations based on these results. Methods A retrospective analysis was performed on TED patients who underwent endoscopic medial wall, orbital floor, and/or open lateral wall decompression. We evaluated the influence of preoperative comorbidities, anatomic and laboratory values, and surgical approach on postdecompression Hertel exophthalmometry outcomes. Results Analysis encompassed 130 orbits from 80 patients, 83% female, 48 with preoperative diplopia, and mean age of 54.4 years. Preoperative Hertel measurement was predictive of extent of proptosis reduction ( P < .0001), indicating that higher initial Hertel measurement predicts greater absolute reduction following surgical intervention. Surgical technique correlated with outcome on univariate analysis ( P = .04), but not multivariate ( P = .13) analyses. When categorized into preoperative Hertel ranges, combined endoscopic medial and open lateral wall decompression resulted in mean proptosis reduction of 3.13 mm for range 20.01 to 24 mm and 3.85 mm for range 24.01 to 28 mm. Three-wall decompression resulted in mean proptosis reduction of 2.49 mm for and 3.84 mm for these ranges, respectively. Variables such as smoking, body mass index, orbital wall height, and TRAb level, did not affect outcomes. Nine patients had new onset diplopia. Conclusions Preoperative Hertel exophthalmometry is the strongest predictor of proptosis reduction following orbital decompression in TED. Surgical technique appears to be less impactful on outcome than expected. Surgical decision making should be individualized based on patient goals; these findings can be used to achieve proptosis reduction and limit the risk of new onset diplopia.
Relationship Between Atrial Dysfunction and Atrial Arrhythmias in Adults With Fontan Palliation: Role of Atrial Strain Imaging
Elzalabany, Sara , Moustafa, Amr , Ali, Ali , Abdelhalim, Ahmed T , Ali, Ahmed E. , Madhavan, Malini , Deshmukh, Abhishek , Egbe, Alexander C.

Journal of the American Heart Association | April 10, 2025 | Volume: 14 | Issue: 8 | Pages: No page available

10.1161/jaha.124.040608 | PMID 40207523 Get It

Background Atrial dysfunction is a risk factor for atrial arrhythmia and can be detected by atrial strain imaging in patients with biventricular circulation. However, the role of atrial strain imaging for risk stratification of atrial arrhythmia in patients with Fontan palliation has not been studied, despite the high prevalence and prognostic implications of atrial arrhythmia in this population. We hypothesized that pulmonary venous atrial strain was associated with new‐onset and recurrent atrial arrhythmia in Fontan physiology. Method and Results This is a retrospective study of adults with Fontan palliation and no prior history of atrial arrhythmia who underwent atrial strain imaging by speckle tracking echocardiography (2003–2023). New‐onset and recurrent atrial arrhythmias were ascertained from baseline encounter to last follow‐up. Of 404 patients, atrial reservoir strain assessment was feasible in 329 patients (81%), with modest intra‐ and interobserver agreement. The median atrial reservoir strain was 18% (interquartile range, 13%–24%), and atrial dysfunction (atrial reservoir strain <28%) was present in 294 (89%). Atrial reservoir strain <15% was associated with new‐onset atrial arrhythmia (adjusted hazard ratio [HR], 1.59 [95% CI, 1.09–2.34]; P =0.009), and recurrent atrial arrhythmia (adjusted HR, 2.01 [95% CI, 1.06–3.93]; P =0.003). Rhythm control therapy was associated with lower risk of recurrence compared with rate control therapy (adjusted HR, 0.92 [95% CI, 0.86–0.98]; P =0.003). Conclusions Atrial dysfunction was common and was associated with new‐onset and recurrent atrial arrhythmias. The higher prevalence of atrial arrhythmias in patients with reduced atrial strain and the apparent protective effect of rhythm control therapy suggest that rhythm control therapy may be the preferred treatment in patients with reduced atrial strain.
Value of Artificial Intelligence for Enhancing Suspicion of Cardiac Amyloidosis Using Electrocardiography and Echocardiography: A Narrative Review
Grogan, Martha , López-Jiménez, Francisco , Guthrie, Spencer , Kumar, Nisith, Langevin, R.Eugene, Lousada, Isabelle , Witteles, Ronald , Royyuru, Ajay K. , Rosenzweig, Michael , Cairns‐Smith, Sarah , Royyuru, Ajay , Ouyang, David , Lopez-Jimenez, Francisco , Kumar, Nisith, Langevin, Reuben

Journal of the American Heart Association | April 10, 2025 | Volume: 14 | Issue: 8 | Pages: No page available

10.1161/jaha.124.036533 | PMID 40207501 Get It

Nonspecific symptoms and other diagnostic challenges lead to underdiagnosis of cardiac amyloidosis (CA). Artificial intelligence (AI) could help address these challenges, but a summary of the performance of these tools is lacking. This narrative review of published literature describes the performance of AI tools that use data from ECGs and echocardiography to improve identification of CA and challenges that hinder adoption of these tools. Thirteen studies met inclusion criteria with sample sizes ranging from 50 to 2451 patients. Four studies used ECG data, 8 used echocardiography data, and 1 used both. The CA gold standard was typically defined as a CA diagnosis in an institutional or other database but the requirements for these diagnoses were heterogenous across studies, and many did not distinguish among CA subtypes. AI model development varied considerably, and only 4 studies included external validation. The ability of models to predict CA ranged from 0.71 to 1.00, sensitivity ranged from 16% to 100%, and specificity from 75% to 100%. Only 1 study reported model performance across strata of sex, age, race, and CA type. Persistent challenges to AI adoption include usability, cost, value added, electronic health record/information technology interoperability, patient‐related factors, regulation, and privacy and liability. Published studies on AI for improved identification of CA show favorable performance measures but numerous methodologic and other challenges must be addressed before these tools are more widely adopted.
Early increase of the synaptic blood marker β‐synuclein in asymptomatic autosomal dominant Alzheimer's disease
Day, Gregory S. , Huey, Edward D. , Xiong, Chengjie , Morris, John C., Roh, Jee Hoon , Otto, Markus , Network, the Dominantly Inherited Alzheimer, Otto, Markus , Day, Gregory S , Xiong, Chengjie , Roh, Jee Hoon , Oeckl, Patrick , Mayer, Benjamin , Bateman, Randall J. , Fox, Nick C. , Ibanez, Laura , Ikeuchi, Takeshi , Jucker, Mathias , Lee, Jae‐Hong , Llibre‐Guerra, Jorge J. , Lopera, Francisco Javier , McDade, Eric , Morris, John C., Niimi, Yoshiki , Sánchez‐Valle, Raquel , Schofield, Peter R. , Network, the Dominantly Inherited Alzheimer

Alzheimer's & Dementia | April 10, 2025 | Volume: 21 | Issue: 4 | Pages: No page available

10.1002/alz.70146 | PMID 40207431 Get It

Abstract INTRODUCTION β‐synuclein is a promising blood marker to track synaptic degeneration in Alzheimer's disease (AD) but changes in preclinical AD are unclear. METHODS We investigated serum β‐synuclein in 69 cognitively unimpaired mutation non‐carriers, 78 cognitively unimpaired AD mutation carriers (asymptomatic AD), and 31 symptomatic mutation carriers from the Dominantly Inherited Alzheimer Network. RESULTS β‐synuclein levels were already higher in asymptomatic AD mutation carriers compared to non‐carriers and highest in symptomatic carriers. Longitudinal trajectories and correlation analyses indicated that β‐synuclein levels start to rise after amyloid deposition preceding axonal degeneration, brain atrophy and hypometabolism, and cognitive decline. β‐synuclein levels were associated with cognitive impairment and gradually increased with declining cognition. DISCUSSION Our study supports the use of blood β‐synuclein to track synaptic changes in preclinical AD and as a surrogate marker for cognitive impairment which might be used in early diagnosis and to support patient selection and monitoring of treatment effects in clinical trials. Highlights Blood β‐synuclein levels were already higher in asymptomatic Alzheimer's disease (AD) mutation carriers. Blood β‐synuclein levels were highest in symptomatic AD mutation carriers. Blood β‐synuclein levels start to rise 11 years before symptom onset. Rise of β‐synuclein precedes axonal degeneration, brain atrophy, and cognitive decline. β‐synuclein levels gradually increased with declining cognition.
Glioblastoma Stem Cells at the Nexus of Tumor Heterogeneity, Immune Evasion, and Therapeutic Resistance
Tang, Justin , Campian, Jian L., Amin, Md Al, Amin, Md. Al

Cells | April 10, 2025 | Volume: 14 | Issue: 8 | Pages: 562

10.3390/cells14080562 | PMID 40277888 Get It

Glioblastoma (GBM) is an exceedingly aggressive primary brain tumor defined by rapid growth, extensive infiltration, and resistance to standard therapies. A central factor driving these malignancies is the subpopulation of glioblastoma stem cells (GSCs), which possess self-renewal capacity, multipotency, and the ability to regenerate tumor heterogeneity. GSCs contribute to key hallmarks of GBM pathobiology, including relentless progression, resistance to chemotherapy and radiotherapy, and inevitable recurrence. GSCs exhibit distinct molecular signatures, enhanced DNA repair, and metabolic adaptations that protect them against conventional treatments. Moreover, they reside within specialized niches—such as perivascular or hypoxic microenvironments—that sustain stemness, promote immunosuppression, and facilitate angiogenesis. Recent discoveries highlight signaling pathways like Notch, Wnt/β-catenin, Hedgehog, STAT3-PARN, and factors such as TFPI2 and HML-2 as critical regulators of GSC maintenance, plasticity, and immune evasion. These findings underscore the complexity of GSC biology and their pivotal role in driving GBM heterogeneity and therapeutic failure. Emerging therapeutic strategies aim to target GSCs through multiple avenues, including surface markers, immunotherapeutics (e.g., CAR T cells), metabolic vulnerabilities, and combination regimens. Advances in patient-derived organoids, single-cell omics, and 3D co-culture models enable more accurate representation of the tumor ecosystem and personalized therapeutic approaches. Ultimately, improved understanding of GSC-specific targets and the tumor microenvironment promises more effective interventions, paving the way toward better clinical outcomes for GBM patients.
Clonal Hematopoiesis of Indeterminate Potential in Chronic Coronary Disease: A Report From the ISCHEMIA Trials Biorepository
Muller, Matthew , Liu, Richard , Shah, Farheen , Held, Claes , Kullo, Iftikhar J. , McManus, Bruce M. , Wallentin, Lars , Newby, L. Kristin , Sidhu, Mandeep S. , Muller, Matthew A , Hu, Jiyuan , Held, Claes , Kullo, Iftikhar J , Wallentin, Lars , Newby, L Kristin , Bangalore, Sripal , Reynolds, Harmony R , Hochman, Judith S , Maron, David J , Ruggles, Kelly V , Berger, Jeffrey S , Newman, Jonathan D , Bangalore, Sripal , Reynolds, Harmony R. , Hochman, Judith S. , Maron, David J. , Berger, Jeffrey S.

Circulation: Genomic and Precision Medicine | April 10, 2025 | Volume: 18 | Issue: 3 | Pages: No page available

10.1161/circgen.124.004921 | PMID 40207358 Get It

Ideas behind bars: the carceral state and struggles for academic freedom in India
Bala, Sruti , Kadiwal, Laila , Kumbamu, Ashok , Nath, Aninthitha, Nath, Aninthitha

Globalisation, Societies and Education | April 10, 2025 | Volume: 24 | Issue: 1 | Pages: 42-60

10.1080/14767724.2025.2482230 Get It

Interpretation of guidelines for diagnosis and treatment of ovarian cancer with integrated traditional Chinese and western medicine
Liu, Jiaxin , Cui, Yongjia, Lü, Wenping , Zhuo, Zhili , Cui, Yongjia , Wang, Jianliu , Yang, Lin

Guidelines and Standards of Chinese Medicine | April 9, 2025 | Volume: 3 | Issue: 2 | Pages: 178-186

10.1097/gscm.0000000000000061 Get It

Ovarian cancer (OC) has the highest mortality rate among gynecologic malignant tumors and is clinically difficult to cure. Traditional Chinese medicine (TCM) has shown unique advantages in the treatment of OC. However, there is currently a lack of normative guidance documents for the treatment of OC with integrated traditional Chinese and western medicine. The guidelines are the first comprehensive approach to diagnosing and treating OC by integrating TCM with western medicine. Adhering to evidence-based principles, the guidelines draw on the most recent advancements in OC treatment from both domestic and international researches. The guidelines formulate a variety of therapeutic methods, including oral Chinese herbal medicine, acupuncture, and external treatments, providing a treatment strategy for the combined use of TCM and western medicine in OC. Furthermore, the guidelines establish a diagnostic and treatment pathway for the holistic management of OC with TCM throughout the disease’s progression. The guidelines were officially published in the China Association of Chinese Medicine in January 2023, which provided a scientific basis for the formulation of clinical diagnosis and treatment strategies and promoted integration with international academic standards. This paper interpreted the features of the guidelines and the 7 PICO issues (Population, Intervention, Comparison, Outcome) in the whole TCM management of OC, aiming to help TCM and western medicine practitioners better understand and apply the guidelines, and provide better medical services for patients with OC.
Accuracy of 18F-Fluorodeoxyglucose Positron Emission Tomography in Early Metastatic Testicular Seminoma: Analysis From the SEMS Trial
Hu, Brian , Cary, Clint , Masterson, Timothy A. , Einhorn, Lawrence H. , Boorjian, Stephen A. , Kollmannsberger, Christian , Schuckman, Anne, So, Alan , Skinner, Eila C., Alemozaffar, Mehrdad, Brand, Timothy C., Eggener, Scott E. , Nappi, Lucia , Nichols, Craig R. , Nappi, Lucia , Alsyouf, Muhannad M. , Farkouh, Ala’a , Adra, Nabil , Black, Peter C. , Bagrodia, Aditya , Pierorazio, Phillip , Stratton, Kelly , Daneshmand, Siamak

Journal of Urology | April 9, 2025 | Volume: 214 | Issue: 3 | Pages: 272-279

10.1097/ju.0000000000004561 | PMID 40203124 Get It

Advancing the Evaluation and Management of CDH1-Associated Gastric Cancer
Lerner, Benjamin A. , Gupta, Samir , Burke, Carol A. , Samadder, Jewel, Yurgelun, Matthew B. , Kelly, Kaitlyn J. , Prats, Mariana Moreno, Joseph, Nora, Idos, Gregory , Swanson, Benjamin , Kieber‐Emmons, AnnMarie, Llor, Xavier , Gupta, Samir , Samadder, Jewel J., Gupta, Samir , Burke, Carol A , Kupfer, Sonia S. , Katona, Bryson W , Grady, William M. , Weiss, Jennifer M.

Journal of the National Comprehensive Cancer Network | April 9, 2025 | Volume: 23 | Issue: 4 | Pages: No page available

10.6004/jnccn.2025.7006 | PMID 40203872 Get It

Gastric cancer is a significant global health concern, with CDH1-associated gastric cancer representing a small but important subset of cases. Historically, individuals with CDH1 pathogenic germline variants were advised to undergo prophylactic total gastrectomy due to the high reported risk of gastric cancer and the limited sensitivity of upper endoscopy in detecting signet ring cell carcinoma (SRCC). However, emerging data suggest that the cumulative lifetime risk of advanced gastric cancer among CDH1 germline pathogenic variant carriers is lower than previously thought, and early-stage SRCC detected on endoscopy does not necessarily indicate imminent—or even eventual—progression to advanced cancer. The near-universal presence of T1a SRCC in gastrectomy specimens from asymptomatic CDH1 pathogenic variant carriers calls into question the reflexive recommendation for gastrectomy, including upon detection of SRCC during surveillance. Furthermore, the morbidity and quality-of-life impact associated with total gastrectomy require careful consideration. Active endoscopic surveillance has shown promise as an alternative management strategy for gastrectomy in patients lacking indicators of >T1a SRCC, though current data are limited by short follow-up periods and selection bias. This review synthesizes recent findings on the natural history of CDH1-associated gastric cancer and evaluates the risks and benefits of gastrectomy versus active endoscopic surveillance, with the goal of helping clinicians provide personalized and evidence-based recommendations for patients with CDH1 pathogenic variants.